Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT07726329
Active, not recruiting Phase 2

Dendritic Cell-immunotherapy for Advanced Hepatocellular Carcinoma

NCT07726329 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Chang Gung Memorial Hospital
Phase
Phase 2
Started
2019-07-01
Last updated
2026-07-24

Condition(s) studied

Liver Neoplasms

Investigational drug(s) / intervention(s)

dendritic cells

dendritic cells: autologous dendritic cell vaccination

Study summary

The prognosis of advanced hepatocellular carcinoma is poor. In this study, the eligible patients will be treated by tumor antigen-pulsed autologous dendritic cells and followed by TACE. The end points are to see tumor response and patient survival.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * advanced HCC patients, no response to standard treatment; WBC : 3000-12000/ul; platelet: \>80000/ul; anticipated survival \> 3 months, measurable tumors. Exclusion Criteria: * HIV; BCLC stage; acute infection; sepsis; other advanced malignancy; acute liver failure;

Primary outcome measure(s)

  • Incidence of Treatment-Related Adverse Events — up to 48 months.
    To evaluate the safety of the treatments by assessing the number of participants with treatment-related adverse events.
  • Objective Tumor Response — From date of first treatment until the date of first documented progression, assessed up to 48 months.
    To evaluate the tumor responses under the treatments as assessed by modified RECIST criteria.

Trial sites (1)

FacilityCityRegionStatus
Chang-Gung Memorial Hospital Taoyuan Taiwan

More Chang Gung Memorial Hospital trials in Taiwan

Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC Recruiting
Fractional Exhaled Nitric Oxide and Exacerbations of COPD Starting soon
Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores Recruiting
Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma Recruiting
Effects of Endogenous Gamma Light Stimulation on Brain Oscillations in Cognitively-normal Older Adults Recruiting

Other trials for the same condition

Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating Room Recruiting
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07726329 on ClinicalTrials.gov ↗ ← All trials in Taiwan